Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)

Ticker(s): SPRB

Who's the expert?

Institution: Diabetes Associates Medical Group

Endocrinologist at Diabetes Associated Medical Group (California) who has been in private practice since 1995.
Author of JCEM article Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
Principal investigator and sub-investigator for numerous clinical studies relating to type 1 and type 2 diabetes, anemia and chronic kidney disease, hypoparathyroidism and more.

Interview Goal

This conversation will focus on the potential of tildacerfont in treating CAH. We'll speak to an author of The Journal of Clinical Endocrinology & Metabolism (JCEM) 2021 paper "Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies "

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.